A number of conditions are known to cause a secondary TMA. Screening for secondary causes of TMA must be sent promptly at time of referral as listed on our diagnostic checklist. As part of our referral pathway for new patients with suspected aHUS, eculizumab may be commenced promptly before all of the results of screening for secondary causes of TMA are available.
We aim to review these results in the first month following referral to ensure continued Eculizumab therapy is warranted. There is currently no conclusive evidence that patients with a secondary TMA benefit from treatment with eculizumab.